Dec. 17, 2018 Price forecast | 2 weeks: 0.00% | 1 month: 0.66% | 3 months: 0.77%

PETX stock forecast

Our latest prediction for Aratana Therapeutics, Inc.'s stock price was made on the Dec. 17, 2018 when the stock price was at 5.97$.

In the short term (2weeks), PETX's stock price should underperform the market by 0.00%. During that period the price should oscillate between -7.05% and +8.58%.

In the medium term (3months), PETX's stock price should outperform the market by 0.77%. During that period the price should oscillate between -16.47% and +26.02%.

Create a solid portfolio with PETX

Add PETX to your portfolio and optimize it!

About Aratana Therapeutics, Inc.

Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS.

At the moment the company generates 41M USD in revenues.

On its last earning announcement, the company reported a loss of -0.50$ per share.

The book value per share is 1.96$

Aratana Therapeutics, Inc. website

Three months stock forecastDec. 17, 2018


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
41M 66.59% -12M -28.20% -22M -0.50 - - 45M 1.96 -23M - -26M